Alligator meets primary endpoint with CD40 agonist in pancreatic cancer
Alligator Bioscience has released positive top-line data from the phase II trial assessing the efficacy of the CD40 agonist mitazalimab in pancreatic cancer. Having met the primary endpoint, the company can now start preparing for phase III. Alligator’s CEO Søren Bregenholt stopped by the BioStock studio in Lund to give us a rundown of the results.
Watch the interview with Alligator Bioscience‘s CEO Søren Bregenholt below.
